Bordet Scientific Publications

Bordet Scientific Publications

  • Correction: Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study.

  • Auteurs Roux A, Hervouet L, Di Stefano F, French DP, Giordano L, Ritchie D, Rougé Bugat ME, Keatley D, Cholerton R, McWilliams L, Giorgi Rossi P, Balleyguier C, Guindy M, Gilbert FJ, Burrion JB, Roman M, Vissac-Sabatier C, Couch D, Delaloge S, de Montgolfier S
  • Revue BMC Cancer
  • Date de publication 2025-04
Correction: Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study.
  • Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.

  • Auteurs Maurer C, Agostinetto E, Ameye L, Lambertini M, Martel S, Ponde N, Brandão M, Poggio F, Ferreira A, Schiff R, De Angelis C, Gelber RD, Dent S, Thomssen C, Piccart M, de Azambuja E
  • Revue Breast Cancer Res Treat
  • Date de publication 2025-04
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.
  • Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.

  • Auteurs Martínez C, Khvedelidze I, Fekom M, Deau Fischer B, Marouf A, Ghesquières H, Fornecker LM, Merli F, Stefani PM, Massaro F, Botto B, Ferhanoğlu B, Akay OM, Özbalak M, Espeso de Haro M, Romero S, Galimard JE, Glass B, Bazarbachi A, Sureda A
  • Revue Bone Marrow Transplant
  • Date de publication 2025-04
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.
  • Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.

  • Auteurs Biganzoli G, Isnaldi E, Richard F, Marano G, Boracchi P, Maetens M, Floris G, Neven P, Jerusalem G, Munzone E, Hitre E, Gombos A, Thompson A, Aebi S, Kammler R, Dell'Orto P, Viale G, Regan MM, Colleoni M, Biganzoli E, Desmedt C
  • Revue Eur J Cancer
  • Date de publication 2025-04
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.
  • Acoustic Features of Airway Protective Maneuvers as Biomarkers of Radiation-Associated Dysphagia and Penetration/Aspiration in Head and Neck Cancer Patients.

  • Auteurs Mootassim-Billah S, Schoentgen J, De Bodt M, Slama H, Willemse E, Dragan T, Roper N, Le Tensorer M, Kristanto P, Paesmans M, Van Gestel D, Van Nuffelen G
  • Revue Head Neck
  • Date de publication 2025-04
Acoustic Features of Airway Protective Maneuvers as Biomarkers of Radiation-Associated Dysphagia and Penetration/Aspiration in Head and Neck Cancer Patients.
Erasme hospital

Erasme Hospital

View all of Erasme's scientific publications

Huderf hospital

Queen Fabiola Children's Hospital

View all scientific publications from the Queen Fabiola Children's Hospital

Decorative image of doctor and patient

All scientific publications by the H.U.B.

View all scientific publications from the H.U.B.